BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37564651)

  • 1. Transcriptomic profile of
    Marzano P; Balin S; Terzoli S; Della Bella S; Cazzetta V; Piazza R; Sandrock I; Ravens S; Tan L; Prinz I; Calcaterra F; Di Vito C; Cancellara A; Calvi M; Carletti A; Franzese S; Frigo A; Darwish A; Voza A; Mikulak J; Mavilio D
    Front Immunol; 2023; 14():1208662. PubMed ID: 37564651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine.
    Boulouis C; Kammann T; Cuapio A; Parrot T; Gao Y; Mouchtaridi E; Wullimann D; Lange J; Chen P; Akber M; Rivera Ballesteros O; Muvva JR; ; Smith CIE; Vesterbacka J; Kieri O; Nowak P; Bergman P; Buggert M; Ljunggren HG; Aleman S; Sandberg JK
    Mol Med; 2022 May; 28(1):54. PubMed ID: 35562666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulated CD8
    Dou X; Peng M; Jiang R; Li W; Zhang X
    Front Immunol; 2023; 14():1174406. PubMed ID: 37654490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability.
    Graydon EK; Conner TL; Dunham K; Olsen C; Goguet E; Coggins SA; Rekedal M; Samuels E; Jackson-Thompson B; Moser M; Lindrose A; Hollis-Perry M; Wang G; Maiolatesi S; Alcorta Y; Reyes A; Wong M; Ramsey K; Davies J; Parmelee E; Ortega O; Sanchez M; Moller S; Inglefield J; Tribble D; Burgess T; O'Connell R; Malloy AMW; Pollett S; Broder CC; Laing ED; Anderson SK; Mitre E
    Front Immunol; 2023; 14():1225025. PubMed ID: 37711632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
    Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G;
    J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection.
    Sedegah M; Porter C; Goguet E; Ganeshan H; Belmonte M; Huang J; Belmonte A; Inoue S; Acheampong N; Malloy AMW; Hollis-Perry M; Jackson-Thompson B; Ramsey KF; Alcorta Y; Maiolatesi SE; Wang G; Reyes AE; Illinik L; Sanchez-Edwards M; Burgess TH; Broder CC; Laing ED; Pollett SD; Villasante E; Mitre E; Hollingdale MR
    PLoS One; 2022; 17(10):e0276241. PubMed ID: 36251675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing.
    Tong R; Luo L; Zhao Y; Sun M; Li R; Zhong J; Chen Y; Hu L; Li Z; Shi J; Lyu Y; Hu L; Guo X; Liu Q; Shuang T; Zhang C; Yuan A; Sun L; Zhang Z; Qian K; Chen L; Lin W; Chen AF; Wang F; Pu J
    Emerg Microbes Infect; 2023 Dec; 12(1):e2187245. PubMed ID: 36987861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated CD21
    Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
    J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals.
    Lozano-Rodríguez R; Avendaño-Ortíz J; Terrón V; Montalbán-Hernández K; Casalvilla-Dueñas J; Bergón-Gutiérrez M; Mata-Martínez P; Martín-Quirós A; García-Garrido MÁ; Del Balzo-Castillo Á; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; López-Morejón L; Vela-Olmo C; Cubillos-Zapata C; López-Collazo E; Del Fresno C
    Front Immunol; 2023; 14():1136029. PubMed ID: 37153580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered.
    López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A
    Front Immunol; 2023; 14():1129753. PubMed ID: 37006309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2.
    Kageyama T; Tanaka S; Etori K; Hattori K; Miyachi K; Kasuya T; Iwamoto T; Ikeda K; Igari H; Yokote K; Nakajima H
    Vaccine; 2022 Mar; 40(14):2129-2133. PubMed ID: 35241300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between a low response to rubella vaccination and reduced anti-severe acute respiratory syndrome coronavirus 2 immune response after vaccination with BNT162b2: a cross-sectional study.
    Nakaharai K; Nakazawa Y; Mishima Y; Saito M; Shinozaki Y; Yoshida M
    Clin Microbiol Infect; 2023 Feb; 29(2):253.e1-253.e5. PubMed ID: 36150670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project.
    Mageau A; Tchen J; Ferré VM; Nicaise-Roland P; Descamps D; Delory N; François C; Mendes C; Papo T; Goulenok T; Charles N; Sacré K
    J Autoimmun; 2023 Jan; 134():102987. PubMed ID: 36563528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman.
    Di Girolamo L; Ferrara M; Trevisan G; Longo BM; Allice T; Burdino E; Alladio F; Fantino S; Di Perri G; Calcagno A; Bonora S
    Virol J; 2023 Jun; 20(1):123. PubMed ID: 37312093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
    Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
    Front Immunol; 2022; 13():908108. PubMed ID: 35911701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.